{"id":"NCT01440569","sponsor":"Gilead Sciences","briefTitle":"Safety and Efficacy of Cobicistat-boosted Darunavir in HIV Infected Adults","officialTitle":"A Phase 3b, Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Cobicistat-boosted Darunavir Plus Two Fully Active Nucleoside Reverse Transcriptase Inhibitors in HIV-1 Infected, Antiretroviral Treatment-Naïve and -Experienced Adults With No Darunavir Resistance-associated Mutations","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-09","primaryCompletion":"2012-08","completion":"2015-10","firstPosted":"2011-09-26","resultsPosted":"2014-10-28","lastUpdate":"2016-12-14"},"enrollment":314,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Acquired Immunodeficiency Syndrome","HIV Infections"],"interventions":[{"type":"DRUG","name":"COBI","otherNames":["Tybost®","GS-9350"]},{"type":"DRUG","name":"DRV","otherNames":["Prezista®","TMC114"]},{"type":"DRUG","name":"NRTIs","otherNames":[]}],"arms":[{"label":"COBI-boosted DRV","type":"EXPERIMENTAL"}],"summary":"This study is to evaluate the safety and tolerability of cobicistat-boosted darunavir plus two fully active nucleoside analogue reverse transcriptase inhibitors in HIV 1 infected, antiretroviral treatment-naive and treatment-experienced adults with no darunavir (DRV) resistance-associated mutations.\n\nAfter the Week 48 Visit, participants will be given the option to participate in an open-label rollover phase to receive cobicistat and attend visits every 12 weeks until it becomes commercially available, or until Gilead Sciences elects to terminate development of cobicistat.","primaryOutcome":{"measure":"Percentage of Participants With Onset of Any Treatment-emergent Grade 3 or 4 Adverse Event Between Baseline and Week 24","timeFrame":"Up to 24 weeks","effectByArm":[{"arm":"Treatment-Naive","deltaMin":5.4,"sd":null},{"arm":"Treatment-Experienced","deltaMin":11.1,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":15,"exclusionCount":14},"locations":{"siteCount":49,"countries":["United States","Puerto Rico"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":45,"n":295},"commonTop":["Diarrhoea","Nausea","Upper respiratory tract infection","Headache","Nasopharyngitis"]}}